ITOS - iTeos Therapeutics, Inc.
IEX Last Trade
7.31
0.030 0.410%
Share volume: 5,387
Last Updated: Fri 27 Dec 2024 08:30:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$7.28
0.03
0.41%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-12 | 2022-08-10 | 2022-11-10 | 2023-03-15 | 2023-05-10 | 2023-08-08 | 2023-11-07 | 2024-03-06 | |
| Assets | |||||||||
| Total Assets | 850.321 M | 814.774 M | 777.873 M | 754.991 M | 728.346 M | 703.746 M | 677.644 M | 667.588 M | |
| Current Assets | 840.660 M | 804.743 M | 768.546 M | 628.298 M | 615.401 M | 614.547 M | 619.128 M | 550.652 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 12.057 M | 8.878 M | 11.740 M | 14.135 M | 12.831 M | 14.890 M | 20.101 M | 18.601 M | |
| Short Term Investments | 12.057 M | 8.878 M | 11.740 M | 14.135 M | 12.831 M | 14.890 M | 20.101 M | 18.601 M | |
| Total Receivables | 4.619 M | 4.004 M | 4.563 M | 1.001 M | 433.000 K | 433.000 K | 0.000 | 135.000 K | |
| Current Cash | 823.984 M | 791.861 M | 752.243 M | 613.162 M | 602.137 M | 599.224 M | 599.027 M | 531.916 M | |
| Total Non-current Assets | 9.661 M | 10.031 M | 9.327 M | 126.693 M | 112.945 M | 89.199 M | 58.516 M | 116.936 M | |
| Property Plant Equipment | 2.216 M | 2.271 M | 2.095 M | 2.121 M | 2.119 M | 2.548 M | 3.330 M | 4.696 M | |
| Other Assets | 1.915 M | 2.678 M | 2.525 M | 1.460 M | 1.505 M | 2.694 M | 3.109 M | 5.391 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 850.321 M | 814.774 M | 777.873 M | 754.991 M | 728.346 M | 703.746 M | 677.644 M | 667.588 M | |
| Total liabilities | 223.943 M | 177.473 M | 143.674 M | 91.659 M | 76.084 M | 80.220 M | 79.382 M | 92.360 M | |
| Total current liabilities | 174.253 M | 125.395 M | 93.831 M | 42.000 M | 26.358 M | 30.023 M | 28.223 M | 40.014 M | |
| Accounts Payable | 10.603 M | 10.921 M | 9.603 M | 7.662 M | 5.694 M | 5.227 M | 3.419 M | 11.293 M | |
| Other liabilities | 45.229 M | 48.049 M | 46.115 M | 45.822 M | 45.965 M | 45.770 M | 46.347 M | 47.539 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 45.229 M | 48.049 M | 46.115 M | 45.822 M | 45.965 M | 45.770 M | 46.347 M | 47.539 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 626.378 M | 637.301 M | 634.199 M | 663.332 M | 652.262 M | 623.526 M | 598.262 M | 575.228 M | |
| Common stock | 35.493 M | 35.547 M | 35.575 M | 35.593 M | 35.716 M | 35.769 M | 35.783 M | 35.786 M | |
| Retained earnings | 210.205 M | 215.831 M | 216.822 M | 237.275 M | 221.724 M | 187.424 M | 155.183 M | 124.633 M |